Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced vasculitis.

Mittie K Doyle1, Marta L Cuellar

  • 1Tulane University Health Sciences Center, Department of Medicine, Section of Clinical Immunology, Allergy & Rheumatology, 1700 Perdido Street, SL-57 New Orleans, LA 70112, USA. mdoyle1@tulane.edu

Expert Opinion on Drug Safety
|August 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet (London, England)·2022
Same author

Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.

The journal of pain·2019
Same author

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Annals of the rheumatic diseases·2014
Same author

The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.

The American journal of the medical sciences·2013
Same author

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.

Annals of the rheumatic diseases·2013
Same author

Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

Arthritis care & research·2013
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026
See all related articles

Drug-induced vasculitis can mimic idiopathic forms and present with varied symptoms. Prompt diagnosis and withdrawal of the causative medication often lead to resolution without further immunosuppression.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Immunology

Background:

  • Drug-induced vasculitis is a serious adverse reaction to medications.
  • It can manifest with diverse clinical presentations, resembling idiopathic vasculitis.
  • Various pharmacological classes are associated with its development.

Purpose of the Study:

  • To review the clinical spectrum and pathogenic mechanisms of drug-induced vasculitis.
  • To emphasize the importance of early diagnosis and management strategies.

Main Methods:

  • Review of existing literature on drug-induced vasculitis.
  • Analysis of clinical manifestations, immunological pathways, and treatment outcomes.

Main Results:

Related Experiment Videos

  • Drug-induced vasculitis presents with symptoms similar to Wegener's granulomatosis, polyarteritis nodosa, and Churg-Strauss syndrome (CSS).
  • Both cell-mediated and humoral immunity are implicated in its pathogenesis.
  • Cutaneous or life-threatening systemic involvement can occur, potentially leading to fatal outcomes.

    • Conclusions:

    • A high index of suspicion is crucial for diagnosing drug-induced vasculitis due to its similarity to idiopathic forms.
    • Discontinuation of the offending drug is often sufficient for clinical resolution.
    • Early identification and drug withdrawal can prevent the need for aggressive immunosuppressive therapies.